Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Long-term monitoring of serum p53 antibody after neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: report of a case.

Shimada H, Nagata M, Cho A, Takiguchi N, Kainuma O, Soda H, Ikeda A, Nabeya Y, Yajima S, Yamamoto H, Sugiyama T, Itami M.

Surg Today. 2014 Oct;44(10):1957-61. doi: 10.1007/s00595-013-0787-y. Epub 2013 Nov 17.

PMID:
24241479
2.

Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma.

Shimada H, Shiratori T, Takeda A, Matsushita K, Okazumi S, Akutsu Y, Matsubara H, Nomura F, Ochiai T.

World J Surg. 2009 Feb;33(2):272-7. doi: 10.1007/s00268-008-9821-4.

PMID:
19052812
3.
4.

Three-year monitoring of serum p53 antibody during chemotherapy and surgery for stage IV rectal cancer.

Suzuki T, Shimada H, Ushigome M, Koike J, Funahashi K, Nemoto T, Kaneko H.

Clin J Gastroenterol. 2016 Apr;9(2):55-8. doi: 10.1007/s12328-016-0633-z. Epub 2016 Feb 26.

PMID:
26919859
5.

Presence of serum p53 antibodies is associated with decreased in vitro chemosensitivity in patients with esophageal cancer.

Shimada H, Okazumi S, Takeda A, Nabeya Y, Matsubara H, Funami Y, Hayashi H, Gunji Y, Suzuki T, Ochiai T.

Surg Today. 2001;31(7):591-6.

PMID:
11495153
6.

Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.

Castoro C, Scarpa M, Cagol M, Ruol A, Cavallin F, Alfieri R, Zanchettin G, Rugge M, Ancona E.

Ann Surg Oncol. 2011 Dec;18(13):3743-54. doi: 10.1245/s10434-011-1753-9. Epub 2011 May 10.

PMID:
21556952
7.

Detection of circulating anti-p53 antibodies in esophageal cancer patients.

Hagiwara N, Onda M, Miyashita M, Sasajima K.

J Nippon Med Sch. 2000 Apr;67(2):110-7.

8.

[Correlation between serum p53 antibody and chemosensitivity in patient with esophageal cancer].

Wang MH, Li YP, Wang XD, Zhang H, Xiong LH, Huang HZ.

Ai Zheng. 2004 Apr;23(4):467-70. Chinese.

PMID:
15087041
9.

Neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: prognostic value of circumferential resection margin and stratification of N1 category.

Saha AK, Sutton C, Rotimi O, Dexter S, Sue-Ling H, Sarela AI.

Ann Surg Oncol. 2009 May;16(5):1364-70. doi: 10.1245/s10434-009-0396-6. Epub 2009 Feb 28.

PMID:
19252949
10.

The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study.

Kandioler D, Schoppmann SF, Zwrtek R, Kappel S, Wolf B, Mittlböck M, Kührer I, Hejna M, Pluschnig U, Ba-Ssalamah A, Wrba F, Zacherl J.

J Thorac Cardiovasc Surg. 2014 Nov;148(5):2280-6. doi: 10.1016/j.jtcvs.2014.06.079. Epub 2014 Jul 22.

11.

Clinical significance of the gene expression profile in residual tumor cells after neoadjuvant chemo-radiotherapy for esophageal cancer.

Tanaka K, Otake K, Mohri Y, Ohi M, Yokoe T, Toiyama Y, Miki C, Tonouchi H, Kusunoki M.

Oncol Rep. 2009 Jun;21(6):1489-94.

PMID:
19424628
12.

Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma.

Shimada H, Takeda A, Arima M, Okazumi S, Matsubara H, Nabeya Y, Funami Y, Hayashi H, Gunji Y, Suzuki T, Kobayashi S, Ochiai T.

Cancer. 2000 Oct 15;89(8):1677-83.

PMID:
11042560
13.

Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy.

Lechpammer M, Lukac J, Lechpammer S, Kovacević D, Loda M, Kusić Z.

Int J Colorectal Dis. 2004 Mar;19(2):114-20. Epub 2003 Nov 21.

PMID:
14634775
14.

Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer.

Watanabe M, Baba Y, Yoshida N, Ishimoto T, Nagai Y, Iwatsuki M, Iwagami S, Baba H.

Ann Surg Oncol. 2014 Sep;21(9):2838-44. doi: 10.1245/s10434-014-3684-8. Epub 2014 Apr 9.

PMID:
24715216
15.

Postoperative chemotherapy vs chemoradiotherapy for thoracic esophageal cancer: a prospective randomized clinical trial.

Tachibana M, Yoshimura H, Kinugasa S, Shibakita M, Dhar DK, Ueda S, Fujii T, Nagasue N.

Eur J Surg Oncol. 2003 Sep;29(7):580-7.

PMID:
12943623
16.

Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.

Pennathur A, Luketich JD, Landreneau RJ, Ward J, Christie NA, Gibson MK, Schuchert M, Cooper K, Land SR, Belani CP.

Ann Thorac Surg. 2008 Jun;85(6):1930-6; discussion 1936-7. doi: 10.1016/j.athoracsur.2008.01.097.

PMID:
18498797
17.

Reduced incidence of nodal micrometastasis after major response to neoadjuvant chemoradiation in locally advanced esophageal cancer.

Prenzel KL, König A, Schneider PM, Schnickmann C, Baldus SE, Schröder W, Bollschweiler E, Dienes HP, Mueller RP, Izbicki JR, Hölscher AH.

Ann Surg Oncol. 2007 Feb;14(2):954-9. Epub 2006 Nov 11.

PMID:
17103071
18.

Treatment response and prognosis of patients after recurrence of esophageal cancer.

Shimada H, Kitabayashi H, Nabeya Y, Okazumi S, Matsubara H, Funami Y, Miyazawa Y, Shiratori T, Uno T, Itoh H, Ochiai T.

Surgery. 2003 Jan;133(1):24-31.

PMID:
12563234
19.

A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246.

Swisher SG, Winter KA, Komaki RU, Ajani JA, Wu TT, Hofstetter WL, Konski AA, Willett CG.

Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1967-72. doi: 10.1016/j.ijrobp.2011.01.043. Epub 2011 Apr 18.

20.

Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer.

Shiga H, Heath EI, Rasmussen AA, Trock B, Johnston PG, Forastiere AA, Langmacher M, Baylor A, Lee M, Cullen KJ.

Clin Cancer Res. 1999 Dec;5(12):4097-104.

Supplemental Content

Support Center